/EVH
EVH Stock - Evolent Health, Inc.
Healthcare|Medical - Healthcare Information ServicesNYSE
$3.99+0.50%
+$0.02 (+0.50%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+50.4%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.95 – $4.03
TARGET (TP)$6.00
STOP LOSS$3.67
RISK/REWARD1:6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.27
52W High$12.98
52W Low$3.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.55B | $1.96B | $1.35B | $907.96M | $924.64M |
| Gross Profit | $367.35M | $460.47M | $316.58M | $250.41M | $228.06M |
| Gross Margin | 14.4% | 23.4% | 23.4% | 27.6% | 24.7% |
| Operating Income | $-40,485,000 | $-71,211,000 | $3.64M | $-42,411,000 | $-262,847,000 |
| Net Income | $-61,623,000 | $-113,040,000 | $-19,164,000 | $-37,601,000 | $-334,246,000 |
| Net Margin | -2.4% | -5.8% | -1.4% | -4.1% | -36.1% |
| EPS | $-0.81 | $-1.28 | $-0.20 | $-0.36 | $-3.94 |
Company Overview
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
82%
Hold / Neutral
2
18%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish2 Neutral/Bearish
Price Targets
$31
Average Target
↑ 671.9% Upside
Now
$7
Low
$31
Average
$46
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Stephens | Upgrade | Overweight | $7 |
| November 13th 2025 | BMO Capital Markets | Initiation | Outperform | $7 |
| January 10th 2025 | Needham | Initiation | Buy | $15 |
| December 3rd 2024 | BTIG Research | Reiterated | Buy | $29← $36 |
| November 8th 2024 | Stephens | Downgrade | Equal Weight | $16← $38 |
| October 11th 2024 | KeyBanc Capital Markets | Initiation | Overweight | $35 |
| August 9th 2024 | Truist | Upgrade | Buy | $33← $28 |
| April 22nd 2024 | Citigroup | Initiation | Buy | $40 |
| March 1st 2024 | Oppenheimer | Initiation | Outperform | $45 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $39 |
| December 6th 2023 | JMP Securities | Initiation | Mkt Outperform | $37 |
| October 16th 2023 | UBS | Initiation | Buy | $46 |
| April 12th 2023 | Stephens | Initiation | Overweight | $40 |
| November 1st 2022 | Truist | Initiation | Hold | $33 |
| July 29th 2022 | RBC Capital Mkts | Initiation | Outperform | $40 |
Earnings History & Surprises
EVHBeat Rate
67%
Last 18 quarters
Avg Surprise
+437.2%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$0.05
Q4 2025
EPS Surprise History
Q1 24
+109.1%
$0.23vs$0.11
Q2 24
+61.9%
$0.34vs$0.21
Q3 24
+42.9%
$0.30vs$0.21
Q4 24
-86.7%
$0.04vs$0.30
Q1 25
-105.3%
$-0.02vs$0.38
Q2 25
-33.3%
$0.06vs$0.09
Q3 25
-211.1%
$-0.10vs$0.09
Q4 25
-50.0%
$0.05vs$0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.06 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.10 | $0.05 | -50.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.09 | $-0.10 | -211.1% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.09 | $0.06 | -33.3% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $0.38 | $-0.02 | -105.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.30 | $0.04 | -86.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.21 | $0.30 | +42.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.21 | $0.34 | +61.9% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.11 | $0.23 | +109.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.09 | $0.30 | +233.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.09 | $0.14 | +55.6% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.15 | $0.21 | +40.0% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $0.06 | $0.10 | +66.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.08 | $0.59 | +637.5% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $0.05 | $0.10 | +105.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.00 | $0.12 | +6085.6% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.01 | $0.08 | +860.4% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.03 | $-0.03 | -8.7% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.06 | $-0.02 | +66.7% | ✓ BEAT |
Latest News
Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $9.5
➖ NeutralBenzinga•Nov 21, 2025, 08:18 PM•Also:
JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 17, 2025, 05:24 PM
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 14, 2025, 05:41 PM•Also:
BMO Capital Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $7
📈 PositiveBenzinga•Nov 13, 2025, 10:47 AM
Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $12
➖ NeutralBenzinga•Nov 12, 2025, 04:23 PM
Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $10
➖ NeutralBenzinga•Nov 10, 2025, 04:38 PM
Citizens Maintains Market Outperform on Evolent Health, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 10, 2025, 01:44 PM
BTIG Maintains Buy on Evolent Health, Lowers Price Target to $16
➖ NeutralBenzinga•Nov 7, 2025, 07:55 PM
Evolent Health shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance.
📈 PositiveBenzinga•Nov 6, 2025, 09:56 PM
Evolent Health, American Oncology Network Announce New Model To Enhance Cancer Care
📈 PositiveBenzinga•Nov 6, 2025, 09:41 PM•Also:
Evolent Health Appoints Mario Ramos CFO, Effective Jan. 1
➖ NeutralBenzinga•Nov 6, 2025, 09:31 PM
Evolent Health Raises FY2025 Sales Guidance from $1.850B-$1.880B to $1.870B-$1.880B vs $1.884B Est
📈 PositiveBenzinga•Nov 6, 2025, 09:13 PM
Evolent Health Sees Q4 Sales $462.000M-$472.000M vs $481.406M Est
📉 NegativeBenzinga•Nov 6, 2025, 09:12 PM
Evolent Health Q3 Adj. EPS $0.05 Misses $0.11 Estimate, Sales $479.533M Beat $473.745M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:12 PM
BTIG Reiterates Buy on Evolent Health, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 10:51 AM
Evolent Health shares are trading higher after the company announced that it has agreed to sell its value-based primary care business, Evolent Care Partners, to Privia Health Group.
📈 PositiveBenzinga•Sep 24, 2025, 03:17 PM•Also:
Stephens & Co. Reiterates Equal-Weight on Evolent Health, Maintains $9 Price Target
➖ NeutralBenzinga•Sep 24, 2025, 12:28 PM
Evolent Health Affirms Q3 Sales Guidance of $460.000M-$480.000M vs $473.745M Est
➖ NeutralBenzinga•Sep 23, 2025, 09:36 PM
Evolent Health Affirms FY2025 Sales Guidance of $1.850B-$1.880B vs $1.884B Est
➖ NeutralBenzinga•Sep 23, 2025, 09:36 PM
Evolent Announces Divestiture Of Its Evolent Care Partners Primary Care Business To Privia, Total Transaction Value Up To $113M; Co. Reiterates Q3 Outlook, Says Proceeds Will Be Used To Prepay Senior Term Debt
📈 PositiveBenzinga•Sep 23, 2025, 08:11 PM•Also:
Frequently Asked Questions about EVH
What is EVH's current stock price?
Evolent Health, Inc. (EVH) is currently trading at $3.99 per share. The stock has moved +0.50% today.
What is the analyst price target for EVH?
The average analyst price target for EVH is $6.00, based on 1 analyst.
What sector is Evolent Health, Inc. in?
Evolent Health, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NYSE exchange.
What is EVH's market cap?
Evolent Health, Inc. has a market capitalization of $0.46 billion, making it a small-cap company.
Does EVH pay dividends?
No, Evolent Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMN
AMN Healthcare Services, Inc.
$16.04
Mkt Cap: $0.6B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
BFLY
Butterfly Network, Inc.
$3.56
Mkt Cap: $0.9B
HSTM
HealthStream, Inc.
$23.94
Mkt Cap: $0.7B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MYGN
Myriad Genetics, Inc.
$6.55
Mkt Cap: $0.6B
NUTX
Nutex Health, Inc.
$171.93
Mkt Cap: $1.0B
PSNL
Personalis, Inc.
$8.55
Mkt Cap: $0.8B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
Explore stocks similar to EVH for comparison